Physician profile
Anthony Tam
NPI 1053687491
$4,504.95
in general payments reported to CMS, 2019-2025
19 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $389 · 2021: $571 · 2022: $843 · 2023: $813 · 2024: $698 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,834.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,727.67 | 2019-2025 | |
| Amarin Pharma, INC. | $791.23 | 2019-2023 | |
| Glaxosmithkline, LLC. | $545.31 | 2019-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $230.83 | 2022-2024 | Jardiance, Mounjaro, Emgality |
| Abbvie INC. | $226.01 | 2019-2024 | Viberzi, Linzess |
| Esperion Therapeutics, INC. | $207.37 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $175.66 | 2020-2024 | Airsupra |
| Novo Nordisk INC | $144.66 | 2020-2024 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $88.61 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.68 | 2022-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $46.41 | 2022 | |
| Amgen INC. | $39.51 | 2019-2023 | Otezla, Repatha |
| Nestle Healthcare Nutrition INC. | $39.12 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $35.69 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $34.73 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $25.46 | 2024 | Cologuard Collection Kit |
| Zimmer Biomet Holdings, INC. | $23.95 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Azurity Pharmaceuticals, INC. | $20.05 | 2023 | Edarbi |
| E.R. Squibb & Sons, L.L.C. | $20.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Tam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.